3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Interventions
Paclitaxel
115
Carboplatin
114
Cisplatin
46
Topotecan
43
Gemcitabine
31
Cyclophosphamide
31
Docetaxel
28
Bevacizumab
28
liposomal doxorubicin
27
Filgrastim
20
pembrolizumab
19
Peripheral Blood Stem Cell Transplantation
18
Taxes
15
Drug Therapy
15
Hyperthermic Intraperitoneal Chemotherapy
13
sargramostim
12
olaparib
12
Immunohistochemistry
11
Chemotherapy, Adjuvant
11
Surgical Procedures, Operative
10
Therapeutics
9
Flow Cytometry
9
Etoposide
9
oregovomab
8
niraparib
8
mirvetuximab soravtansine
8
Psychiatric Rehabilitation
8
Nivolumab
8
Amifostine
8
rucaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
trastuzumab deruxtecan
×
Gynecologic
×
Clear all
NCT06819007
2026-05-26
DO-01
Daiichi Sankyo
Phase 3
Recruiting
582 enrolled